NEW YORK, April 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.co ...

NEW YORK, April 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/sana-biotechnology-inc-loss-submission-form/?id=143343&from=4 CLASS PERIOD: Mar ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, April 16, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA) investors of a class action representing investors that bought securities between March 17, 2023 to November 4, 2024, inclusive (the "Class Period"). SANA investors have until May 20, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Po ...

NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, inclusive (the "Class Period"), of the important May 20, 2025 lead plaintiff deadline. Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www ...

文章核心观点 Faruqi & Faruqi律师事务所调查针对Sana Biotechnology的潜在索赔，提醒投资者5月20日2025年截止日期可争取在联邦证券集体诉讼中担任首席原告，鼓励损失超5万美元投资者联系讨论法律权利 [1][3] 律所信息 - Faruqi & Faruqi是领先的国家证券律师事务所，在多地设有办公室，自1995年成立以来为投资者追回数亿美元 [4] 诉讼指控 - 公司及其高管违反联邦证券法，做出虚假或误导性陈述，未披露公司资金不足、部分产品前景不佳、可能削减产品资金和裁员等情况，夸大财务能力 [5] 公司动态及股价反应 - 2023年10月10日盘后，公司宣布减少体内基因递送平台支出，增加离体细胞疗法平台投入，推迟SG299新药研究申请，减少预期运营消耗并裁员29%，10月11日股价下跌0.34美元/股，跌幅8.95%，收于3.46美元/股 [6][7] - 2024年11月4日盘后，公司宣布暂停肿瘤学SC291和SC379开发，增加1型糖尿病项目投资，延长现金使用期，11月5日股价下跌0.37美元/股，跌幅9.84%，收于3.39美元/股 [8] 首席原告相关 - 法院指定的首席原告是在集体诉讼救济中有最大经济利益、能代表集体成员指导和监督诉讼的投资者，集体成员可申请担任或不作为缺席成员，是否担任不影响赔偿分享 [9] 信息提供与咨询 - 鼓励有Sana公司行为相关信息者联系律所，可访问网站或致电合伙人了解集体诉讼详情 [10]

NEW YORK, April 09, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, inclusive (the "Class Period"), of the important May 20, 2025 lead plaintiff deadline. SO WHAT: If you purchased Sana securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO ...

文章核心观点 Faruqi & Faruqi律师事务所正调查针对Sana Biotechnology的潜在索赔，提醒投资者5月20日2025年截止日期可申请担任联邦证券集体诉讼的首席原告，鼓励在特定时间购买Sana证券受损投资者联系讨论法律权利 [1][3] 律所信息 - Faruqi & Faruqi是领先的国家证券律师事务所，在纽约、宾夕法尼亚、加利福尼亚和佐治亚设有办公室，自1995年成立以来为投资者追回数亿美元 [4] 诉讼指控 - 公司及其高管违反联邦证券法，做出虚假或误导性陈述，未披露公司资金不足、部分产品前景不佳、可能削减产品资金和裁员等情况，夸大公司财务能力 [5] 公司事件及股价反应 - 2023年10月10日盘后，公司宣布减少体内基因递送融合原平台近期支出，增加离体细胞疗法平台投入，推迟SG299新药研究申请，减少预期运营消耗，裁员29%，2024年运营现金消耗低于2亿美元，10月11日股价下跌0.34美元/股，跌幅8.95%，收于3.46美元/股 [6][7] - 2024年11月4日盘后，公司宣布暂停肿瘤学SC291和SC379开发，寻求合作，增加1型糖尿病项目投资，延长现金使用期至2026年，11月5日股价下跌0.37美元/股，跌幅9.84%，收于3.39美元/股 [8] 首席原告相关 - 法院指定的首席原告是在集体诉讼救济中财务利益最大、能代表集体成员的投资者，可选择申请担任或不作为缺席成员，不影响分享赔偿 [9] 信息提供与咨询 - 鼓励知情者包括举报人、前员工、股东等联系律所，可访问网站或致电合伙人了解集体诉讼详情 [10]

NEW YORK, April 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com ...

文章核心观点 Robbins LLP提醒股东针对Sana Biotechnology提起集体诉讼，指控该公司在特定时期误导投资者，真相披露后公司股价下跌损害投资者利益，股东可参与诉讼 [1][2] 分组1：诉讼基本信息 - 集体诉讼代表2023年3月17日至2024年11月4日购买Sana Biotechnology证券的个人和实体提起 [1] - Sana是一家生物技术公司，开发离体和体内细胞工程项目，旨在革新多个未满足治疗需求的治疗领域 [1] 分组2：指控内容 - 被告未披露Sana有资金不足风险，无法维持当前运营和推进产品候选项目 [2] - 肿瘤学的SC291、SC379和SG299项目不如被告向投资者宣称的有前景 [2] - 为保留现金和推进更有前景的产品候选项目，Sana可能减少对上述项目的资金投入或停止项目，并大幅裁员 [2] - 被告夸大了Sana维持当前运营和推进现有产品候选项目的财务能力，真相披露后股价下跌损害投资者 [2] 分组3：后续行动 - 想担任集体诉讼首席原告的股东须在2025年5月20日前向法院提交文件，不参与诉讼也可能获得赔偿 [3] 分组4：律所信息 - Robbins LLP自2002年以来致力于帮助股东挽回损失、改善公司治理结构并追究公司高管责任 [4]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Sana To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Sana between March 17, 2023 and November 4, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, April 06, 2025 (GLOBE NEWSWI ...